호스 테라퓨틱스(HOTH)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.79 (-12.42%), 시가총액 $11.47M, 52주 범위 $0.51 ~ $2.07.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration.
호스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
호스 테라퓨틱스의 현재 주가는 $0.79 (-12.42%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
호스 테라퓨틱스의 시가총액은 약 $11.47M입니다.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States.